Researchers at the University of Michigan are working to develop methods to anticipate recurrence in HPV-positive head and neck cancer sooner. The study revealed clinical and technological perspectives on how to measure if recurrence is happening earlier and suggest better blood tests for monitoring. Paul Swiecicki, M.D., associate medical director, discusses how these new practices differ from current methods and future implications.
